Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 17/20 | 0.78 |
| ▸ | LONP1 | P36776 | 11/20 | 0.78 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.78 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.78 |
| ▸ | PSMB6 | P28072 | 10/20 | 0.78 |
| ▸ | PSMB10 | P40306 | 10/20 | 0.78 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.78 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.78 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.78 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.78 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.78 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.78 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.78 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.78 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.78 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.78 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.78 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.78 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.78 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16362648 | 1.00 | PSMB5 (0.78) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL21558117 | 1.00 | PSMB5 (0.78) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL18848799 | 1.00 | PSMB5 (0.78) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL16492912 | 1.00 | PSMB5 (0.78) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL15145440 | 0.91 | LONP1 (0.68) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL24390721 | 0.90 | PSMB5 (0.80) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL16189897 | 0.90 | PSMB5 (0.80) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL17403817 | 0.90 | PSMB5 (0.80) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL1913443 | 0.90 | PSMB5 (0.76) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL2125752 | 0.90 | PSMB5 (0.76) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2017031084-A1 | POLY(VINYL ALCOHOL) NANOCARRIERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20160368945-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2016-12-22 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | CERULEAN PHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1865950-B1 | COMPOUNDS USEFUL AS MODULATORS OF THE PROTEASOME ACTIVITY | CENTRE NAT RECH SCIENT (FR) | 2013-08-28 | — | — | EP | disclosed |
| WO-2013116200-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368945-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | TBCA, BCL3, BCL6 | PSMB5 1303/4885LONP1 3319/4885PSMB8 1492/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885LONP1 3967/4885PSMB8 1933/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885LONP1 4183/4885PSMB8 1513/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885LONP1 4183/4885PSMB8 1513/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | PSMB5 650/4885LONP1 3292/4885PSMB8 1048/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | PSMB5 650/4885LONP1 3292/4885PSMB8 1048/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885LONP1 3967/4885PSMB8 1933/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885LONP1 3967/4885PSMB8 1933/4885 |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | LPXN, POLI, BRCA1 | PSMB5 1016/4885LONP1 4180/4885PSMB8 763/4885 |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885LONP1 1116/4885PSMB8 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.